anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Platelets not only participate in thrombosis and hemostasis but also interact with tumor cells and protect them from mechanical damage caused by hemodynamic shear stress and natural killer cell lysis, thereby promoting their colonization and metastasis to distant organs. Platelets can affect the tumor microenvironment via interactions between platelet-related factors and tumor cells. Metastasis is a key event in cancer-related death and is associated with platelet-related factors in lung, breast, and colorectal cancers. Although the factors that promote platelet expression vary slightly in terms of their type and mode of action, they all contribute to the overall process. Recognizing the correlation and mechanisms between these factors is crucial for studying the colonization of distant target organs and developing targeted therapies for these three types of tumors. This paper reviews studies on major platelet-related factors closely associated with metastasis in lung, breast, and colorectal cancers.
Skeletal muscle is the largest metabolic organ of the human body. Maintaining the best quality control and functional integrity of mitochondria is essential for the health of skeletal muscle. However, mitochondrial dysfunction characterized by mitochondrial dynamic imbalance and mitophagy disruption can lead to varying degrees of muscle atrophy, but the underlying mechanism of action is still unclear. Although mitochondrial dynamics and mitophagy are two different mitochondrial quality control mechanisms, a large amount of evidence has indicated that they are interrelated and mutually regulated. The former maintains the balance of the mitochondrial network, eliminates damaged or aged mitochondria, and enables cells to survive normally. The latter degrades damaged or aged mitochondria through the lysosomal pathway, ensuring cellular functional health and metabolic homeostasis. Skeletal muscle atrophy is considered an urgent global health issue. Understanding and gaining knowledge about muscle atrophy caused by mitochondrial dysfunction, particularly focusing on mitochondrial dynamics and mitochondrial autophagy, can greatly contribute to the prevention and treatment of muscle atrophy. In this review, we critically summarize the recent research progress on mitochondrial dynamics and mitophagy in skeletal muscle atrophy, and expound on the intrinsic molecular mechanism of skeletal muscle atrophy caused by mitochondrial dynamics and mitophagy. Importantly, we emphasize the potential of targeting mitochondrial dynamics and mitophagy as therapeutic strategies for the prevention and treatment of muscle atrophy, including pharmacological treatment and exercise therapy, and summarize effective methods for the treatment of skeletal muscle atrophy.
Patients will receive CNTO 1275 45 mg at the Weeks 0 and 4 visits. Treatment after Week 12 is dependent on Physician's Global Assessment (PGA) response at Week 12 and initial treatment assignment.
PROBLEM TO BE SOLVED: To produce a rapidly soluble coating agent composition, rapidly soluble at normal temperatures, hardly separating a pigment and capable of forming a film by coating thereof on a tablet such as a medicine. SOLUTION: This coating agent composition is obtained by adding and mixing a powdery pigment with a coating base while spraying a liquid plasticizer thereon. The coating base is a granular hydroxypropyl methyl cellulose or methyl cellulose having 200-1000μm average grain diameter and has <=30wt.% concentration of grains having <=75μm grain diameter. A polyethylene glycol having 190-630 weight average molecular weight is preferred as the plasticizer and blended in an amount of 5-30wt.% based on the coating base. Titanium oxide or an iron oxide or both are used as the pigment and blended in an amount of 1-30wt.% based on the coating base. The viscosity of a 2wt.% aqueous solution of the coating base is preferably 2-60cP. An aqueous coating solution can rapidly be prepared without requiring a special dissolving apparatus and a constant color tone can always be reproduced.
The invention provides a butoconazole nitrate vaginal effervescent tablet including butoconazole nitrate, a filler, a foaming agent and a foam stabilizer, and the butoconazole nitrate accounts for 20-60 wt% in the vaginal effervescent tablet. The foaming agent comprises an acid system comprising acid or acid salt, and an alkali system comprising carbonates. The acid system includes citric acid, tartaric acid, succinic acid, fumaric acid, adipic acid, malic acid, water-soluble amino acid, potassium bitartrate, sodium hydrogen tartrate, sodium bitartrate, potassium dihydrogen citrate, sodium fumarate and boric acid. The alkali system includes sodium bicarbonate, sodium carbonate, potassium bicarbonate, potassium carbonate, calcium bicarbonate and calcium carbonate. The foam stabilizer is a surfactant selected from sodium dodecyl sulfate and Tween 80. The butoconazole nitrate vaginal effervescent tablet provided by the invention can be used for treating vaginal infection diseases caused by candida.
The ENIGMA research consortium develops and applies methods to determine clinical significance of variants in hereditary breast and ovarian cancer genes. An ENIGMA BRCA1/2 classification sub-group, formed in 2015 as a ClinGen external expert panel, evolved into a ClinGen internal Variant Curation Expert Panel (VCEP) to align with Food and Drug Administration recognized processes for ClinVar contributions. The VCEP reviewed American College of Medical Genetics and Genomics/Association of Molecular Pathology (ACMG/AMP) classification criteria for relevance to interpreting BRCA1 and BRCA2 variants. Statistical methods were used to calibrate evidence strength for different data types. Pilot specifications were tested on 40 variants and documentation revised for clarity and ease of use. The original criterion descriptions for 13 evidence codes were considered non-applicable or overlapping with other criteria. Scenario of use was extended or re-purposed for eight codes. Extensive analysis and/or data review informed specification descriptions and weights for all codes. Specifications were applied to pilot variants with pre-existing ClinVar classification as follows: 13 uncertain significance or conflicting, 14 pathogenic and/or likely pathogenic, and 13 benign and/or likely benign. Review resolved classification for 11/13 uncertain significance or conflicting variants and retained or improved confidence in classification for the remaining variants. Alignment of pre-existing ENIGMA research classification processes with ACMG/AMP classification guidelines highlighted several gaps in the research processes and the baseline ACMG/AMP criteria. Calibration of evidence strength was key to justify utility and strength of different data types for gene-specific application. The gene-specific criteria demonstrated value for improving ACMG/AMP-aligned classification of BRCA1 and BRCA2 variants.
Aim: We hypothesized that milk, yogurt, and cheese have differential impacts on energy expenditure (EE) and obesity in mice fed a high-fat diet (HFD). Methods: C57BL/6 mice (n = 16 per group) were fed a HFD or a HFD supplemented with fat-free milk (MILK), fat-free plain yogurt (YOG), or reduced-fat cheddar cheese (CHE; 19 kcal% fat), each provided at 10% of the daily energy intake, for 8 weeks. EE was quantified using a metabolic chamber. Metabolic pathways related to BAT mitochondrial function and uncoupling protein 1 (UCP1) abundance were assessed. Serum lipidomic profiles were analyzed to identify potential mediators of the observed effects. Results: MILK supplementation lowered weight gain and fat accumulation and enhanced EE and BAT thermogenesis, perhaps via the SIRT1-AMPK-PGC1α axis in BAT. This led to elevated UCP1 abundance and enhanced the abundance of hormone-sensitive lipase (HSL). MILK also altered serum lipid species, indicating enhanced energy use, and promoted BAT thermogenesis and mitochondrial function pathways. YOG exhibited a similar pattern but a lower magnitude of effects than MILK on reducing weight gain and fat mass, increasing EE, and BAT thermogenic proteins, including AMPK-PGC1α-UCP1. Both MILK and YOG showed a relative increase in serum PC 15:0_15:0 and LPC 15:0. In contrast, CHE reduced weight gain and increased EE without impacting BAT thermogenesis proteins or serum lipid species. Conclusion: Our study showed that MILK, YOG, and CHE reduced weight gain in mice on a HFD by increasing EE. MILK and YOG also up-regulated BAT thermogenesis, while both additionally altered lipids involved in fat metabolism and inflammation. CHE did not affect BAT thermogenesis and lipid species compared to HFD.
Reflexology was performed in those in the intervention group after CS on right foot for 10 min and left foot for 20 min as continuing 30-min seances three times per day every eight hours for three days. The procedure was started at mean 3rd hour after mothers became stable. Reflexology was performed for none of those in the control group.
Knee osteoarthritis (OA) is a chronic disease characterized by morning stiffness, reduced joint range of motion, chronic pain, and decreased muscle strength, leading to functional limitations as the disease progresses . In patients with knee osteoarthritis, all muscles of the hip, knee, and ankle are affected in some way . Evidence suggests that impairments in muscle strength in the lower extremities contribute to increased pain and joint space narrowing. Voluntary muscle contractions lead to various changes in muscle architecture, including changes in fascicle angle and pennation angle as well as muscle thickness. While muscle cross-sectional area and thickness are primarily associated with the magnitude of generated force, parameters such as pennation angle have been found to be more related to explosive force. Ultrasonography (US) is a non-invasive imaging method that can visualize these changes. Muscle architecture parameters obtained from US can provide reliable data related to muscle contractility independently of surrounding muscles. Furthermore, US is considered to have similar validity to MRI imaging, which is the gold standard for displaying muscle architecture. Additionally, isometric muscle strength can be reliably measured using handheld dynamometers. Although studies have investigated the relationship between muscle strength and muscle architecture determined by US in patients with knee OA, these studies have predominantly examined the relationship in the quadriceps muscle, and muscles associated with the ankle have not been studied extensively.
PURPOSE: Physical activity can provide analgesic benefit but its effect on cancer-related pain is unclear. This review synthesised and appraised the evidence for the effect of physical activity on pain in people living with or beyond cancer.
METHODS: A systematic search of Ovid Medline and Embase was performed to identify randomised controlled trials (RCTs), randomised cross-over studies (RXTs), and prospective observational studies that examined physical activity and pain outcomes in adults living with or beyond cancer. Meta-analyses were performed to generate effect estimates. Risk of bias was assessed, and the GRADE system was used to assess evidence quality.
RESULTS: One hundred twenty-one studies (n = 13,806), including 102 RCTs, 6 RXTs, and 13 observational studies, met the criteria for inclusion. Meta-analyses of RCTs identified a decrease in pain intensity (n = 3734; standardised mean difference (SMD) - 0.30; 95% confidence interval (CI) - 0.45, - 0.15) and bodily pain (n = 1170; SMD 0.28; 95% CI 0.01, 0.56) but not pain interference (n = 207; SMD - 0.13, 95% CI - 0.42, 0.15) following physical activity interventions. Individual studies also identified a reduction in pain sensitivity but not analgesic use, although meta-analysis was not possible for these outcomes. High heterogeneity between studies, low certainty in some effect estimates, and possible publication bias meant that evidence quality was graded as very low to low.
CONCLUSION: Physical activity may decrease pain in people living with and beyond cancer; however, high heterogeneity limits the ability to generalise this finding to all people with cancer or to specific types of cancer-related pain.
PURPOSE:To obtain a bathing agent composition, capable of imparting good bath feeling and excellent in powder fluidity, powder non-aggregation properties and solubility in hot water. CONSTITUTION:A bathing agent composition is obtained by blending (A) a water-swellable clay mineral, e.g. a natural or a synthetic smectite family clay mineral such as montmorillonite, saponite or hectorite with (B) an oily ingredient, e.g. an oily substance a humectant such as an animal or a vegetable oil, an ester oil, higher alcohol, a hydrocarbon oil or silicones, a perfume, etc., and (C) inorganic salts, e.g. sodium sulfate, magnesium sulfate sodium carbonate, sodium biarbonate, sodium chloride or potassium chloride as essential ingredients. The resultant bathing agent composition has the above-mentioned effects. Furthermore, although the amount of the ingredient (A) depends on the amount of the ingredient (B) such as the humectant or oils, the amount is preferably about 0.5-5 times based on the ingredient (B). Besides the essential ingredients, organic acids, herb medicines, water-soluble polymers, coloring matters etc., can suitably be blended in the above-mentioned bathing agent composition.
CASE: A 79-year-old woman presented with a periprosthetic fracture 8 years after a total knee arthroplasty (TKA). Radiographs demonstrated tibial implant loosening with severe osteolysis. A high-grade osteosarcoma around the prosthesis was diagnosed, and a supracondylar femoral amputation was performed. After 2 years, no complications have occurred.
CONCLUSIONS: A malignant tumor around a TKA is extremely rare. Surgeons should remain vigilant with patients who present with rapidly progressive or very aggressive implant loosening with osteolysis. Owing to its complexity and potentially devastating prognosis, treatment should be guided by a specialist multidisciplinary team. Complex limb salvage procedures or amputation is usually required.
<P>PROBLEM TO BE SOLVED: To obtain a hypotensive agent exhibiting excellent hypotensive actions and to provide a method for producing the same and to obtain a propolis composition and a food formulation.  <P>SOLUTION: The hypotensive agent and the food formulation comprise at least one kind selected from compounds represented by formula (1) (wherein, X is hydrogen, an alkoxyl group, hydroxy group, a caffeoyloxy group or a p-coumaroxy group, with the proviso that the carbon number of the alkoxyl group is 1-3). The method for producing the hypotensive agent comprises an extraction step, a separation step and a collection step. In the extraction step, polyphenols are extracted from a polyphenol-containing material and the resultant component is separated in the separation step. In the collection step, at least the one kind selected from the compounds represented by formula (1) is collected using fluorescence from excitation light in an ultraviolet region as an index. The propolis composition comprises at least the one kind selected from the compounds in addition to a propolis extract.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
The invention relates to a pill for treating hemiplegia. The pill is an internal pill of a Chinese patent medicine for treating hemiplegia, facial paralysis, stiff tongue and sluggish speech and the like. Through research for many years and clinical practical verification, the pill consists of hemiplegia, scorpio, earthworm, gastrodia elata, uncaria, monkshood, leech, rhizoma arisaematis, Pinellia ternate, flowers carthami, long-noded pit viper, centipede, rhizoma acori graminei and concha haliotidis. The pill is prepared by casting the medicines in weight ratio according to a formula; smashing to 120 meshes, and preparing a honeyed pill by a traditional Chinese medicine pill preparation method. Each pill is 9g in weight. The pill provided by the invention is clear in rules of treatment and reasonable in compatibility of medicines, has the function of eliminating phlegm by cooling, promoting blood circulation to remove blood stasis, and dredging collaterals and the like, and can treat diseases such as hemiplegia, facial paralysis, stiff tongue and sluggish speech. The pill is good in curative effect and quick to effect, and the effective rate reaches 100%. The medicine has the effect of treating both manifestation and root cause of disease, and can realize the purpose of difficulty in relapse after healing.
Participants who received primary vaccination in study V48P7 on Days 0, 7 (+3) and 21 (+7) (66 participants) and who received a booster vaccination either in study V48P7E1 (NCT00387634) (9 participants) or before enrolment in study V48P7E1 (NCT00387634) (40 participants). For these participants a second booster vaccination within six months after the annual blood draw was to be administered within the present study only in case their NT titer resulted below 10.
Participants will follow their usual diet and lifestyle but also be provided with 1 avocado to consume per day for 6 months. To maximize compliance, participants will be provided with resources on how to choose, store and ripen avocados along with simple usage ideas. Specific nutrition guidance will not be provided. Participants will pick up fresh avocados every 2 weeks with minimal interaction with study personnel. Compliance visits will be conducted monthly.
A total of 6 sessions of face-to-face group CBT-I therapy will be provided. Each session will last 90-120 mins, with each group 8-10 subjects.
This study is for first line treatment for multiple myeloma patients in patients \>65 years or have renal insufficiency Busulfan introduces cytopenia much slower than melphalan while the time to recover after transplantation is the same. The duration of cytopenia with busulfan should therefore be shorter. Busulfan given in myeloma patients with renal failure has proven to be effective.

The initial proposed dose level in our study will be 3.2mg/kg of body weight over 6 hours for 3 days. The next levels will be 3.2mg/kg of body weight over 6 hours for 4 days, 4.3 mg/kg of body weight over 6 hours for 3 days, 5.6 mg/kg of body weight over 6 hours for 2 days, and 6.4 mg/kg of body weight over 6 hours for 2 days. Three patients per group will be entered at the first level. Further enrollment will be dependent upon toxicities observed. All dose escalations will be initiated after the PI has reviewed the toxicity data available on the prior dose levels and confirms that it is safe to proceed to subsequent dose level(s). Maximum tolerated dose will defined as the dose level immediately below the dose level at which ≥ 2 of 6 patients experiences a grade 4 non-hematological toxicity that is unexpected, related, and serious, and it will be evaluated separately for patients \> 65 years of age or in patients with renal insufficiency.
Participants will be randomly assigned to one of the three treatment sequences (T1T2R, T2RT1, RT1T2). In each treatment sequences, participants will cross-over to three periods taking different formulations of entrectinib. Entrectinib will be administered as a single 600 milligram (mg) oral dose under fed condition in three different formulations. Test formulation 1 (T1): film-coated mini-tablet; Test formulation 2 (T2): film-coated mini-tablet; Reference formulation (R): hard capsule.
All subjects were required to receive BurstDR stimulation therapy for the first 3 months after permanent implant. Thereafter the stimulation mode could be changed to tonic stimulation depending on patient's preference or physician's discretion.
The invention relates to a nutrient delivery system based on burdock glycoprotein and a preparation method and application thereof, wherein the preparation method comprises the following steps: step 1: separating to obtain burdock glycoprotein. And 2, step: and (3) carrying out ultrasonic disruption treatment on the burdock glycoprotein. And step 3: and loading nutrients. And 4, step 4: and (3) assembling burdock glycoprotein nanoparticles. The nutrient delivery system of the present invention is obtained. The chemical composition is simple, the cost is controllable, the effective regulation and control of the size of a delivery system can be realized by changing the parameters of ultrasonic crushing treatment in the early stage according to the product requirements, the nanoparticle with the core-shell structure is formed by combining the acidic ethanol treatment and the ultrahigh pressure treatment, the use of toxic chemicals is not involved, and the environment is friendly. The whole preparation process is carried out at normal temperature or low temperature, so that flavor change and nutrient activity reduction caused by heating are effectively inhibited.
Purpose: Prior literature evaluating the importance of timely second-dose antibiotics in patients with sepsis has led to better outcomes and a possible reduction in mortality, length of mechanical ventilation, and length of time requiring vasopressors. Objective: To evaluate the impact of a newly developed pharmacist-led two-dose cefepime protocol implemented within an emergency department (ED) service. Methods: This was a retrospective, single-center, pre-post observational cohort study. Institutional review board approval was obtained. The primary endpoint was a reduction in time between the first and the second doses of antibiotics for patients with sepsis who present to the emergency department. Secondary endpoints included length of vasopressor therapy, intensive care unit (ICU) length of stay, hospital length of stay, duration of mechanical ventilation, and mortality. Results: A total of 84 patients were included in the pharmacist-led two-dose hospital protocol and 79 patients were included in the historical control. In the control cohort, the median time between the first and second dose of antibiotics was 12 hours vs 8.5 hours in the tested cohort. The average time requiring vasopressors was 1.20 days for the control cohort vs .46 days for the post-implementation group. Lastly, the median hospital length of stay in days was 8 for the control group vs 7 for the tested cohort. Conclusion: Implementation of a pharmacist-led two-dose cefepime protocol was associated with a numerically lower duration between second-dose antibiotics, days requiring vasopressors, and a slight reduction in hospital length of stay.
Alzheimer's disease (AD) is a progressive multifaceted neurodegenerative disease and remains a formidable global health challenge. The current medication for AD gives symptomatic relief and, thus, urges us to look for alternative disease-modifying therapies based on a multitarget directed approach. Looking at the remarkable progress made in peptide drug development in the last decade and the benefits associated with peptides, they offer valuable chemotypes [multitarget directed ligands (MTDLs)] as AD therapeutics. This review recapitulates the current developments made in harnessing peptides as MTDLs in combating AD by targeting multiple key pathways involved in the disease's progression. The peptides hold immense potential and represent a convincing avenue in the pursuit of novel AD therapeutics. While hurdles remain, ongoing research offers hope that peptides may eventually provide a multifaceted approach to combat AD.